Survival analysis identified poor prognostic factors: high PSS (P = 0.015), lymph node metastasis (P = 0.015), substantial intraoperative blood loss (P = 0.013), low preoperative CD8+ T cells (P = 0.001), and low postoperative IL-17 (P = 0.013). The gene discussed is IL17A; the disease is metastatic malignant neoplasm in the lymph nodes.